Daré Bioscience (NASDAQ:DARE) Stock Price Passes Below 200-Day Moving Average – Time to Sell?

Daré Bioscience, Inc. (NASDAQ:DARE)’s stock price passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $3.29 and traded as low as $2.88. Daré Bioscience shares last traded at $2.89, with a volume of 11,376 shares traded.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Daré Bioscience in a report on Tuesday, December 17th.

Daré Bioscience Trading Up 0.3 %

The company has a market capitalization of $25.14 million, a PE ratio of -4.89 and a beta of 1.38. The company’s 50 day moving average price is $3.08 and its 200-day moving average price is $3.29.

Institutional Investors Weigh In On Daré Bioscience

Several institutional investors and hedge funds have recently added to or reduced their stakes in DARE. Geode Capital Management LLC grew its holdings in shares of Daré Bioscience by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock worth $289,000 after purchasing an additional 3,593 shares during the period. Renaissance Technologies LLC lifted its position in Daré Bioscience by 6.7% during the fourth quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 4,300 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Daré Bioscience in the fourth quarter worth $52,000. Finally, AMH Equity Ltd raised its stake in shares of Daré Bioscience by 50.0% in the 4th quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 50,000 shares during the period. 6.70% of the stock is currently owned by institutional investors and hedge funds.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.